This review assessed the effectiveness of adjuvant therapy following surgery for early ovarian cancer. The authors concluded there was no significant difference in survival between chemotherapy and radiotherapy and, that chemotherapy improved survival compared with no treatment. Toxicity and quality of life were not evaluated. Lack of assessment of the differences between included studies limits the strength of this review.
Authors' objectives
To assess the effectiveness of adjuvant treatment after surgery in women with early ovarian cancer.
Searching MEDLINE (from 1975) , EMBASE (from 1980), Cancerlit and the Cochrane CENTRAL Register were searched; the search terms were stated.
Study selection Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible for inclusion.
Specific interventions included in the review
Studies of adjuvant treatment with chemotherapy or radiotherapy were eligible for inclusion. Studies of different types, doses, or regimens of a single treatment modality were excluded. The review included studies that compared adjuvant radiotherapy with no treatment; chemotherapy with radiotherapy; radiotherapy plus chemotherapy with radiotherapy alone; and chemotherapy with no treatment. The radiotherapy regimens included intraperitoneal radioactive chronic phosphate (P32) and whole abdominal-pelvic radiotherapy. The chemotherapy regimens included cisplatin-based regimens and melphalan regimens.
Participants included in the review
Studies of women with early epithelial ovarian cancer (Stage I or II) were eligible for inclusion. Only studies in which women had formal surgical staging of the cancer performed at laparotomy were included in the meta-analysis.
Outcomes assessed in the review
Studies that reported survival were eligible for inclusion. The primary outcomes in the review were overall survival and disease-free survival.
How were decisions on the relevance of primary studies made? Two reviewers independently selected the studies for inclusion and resolved any disagreements through discussion.
Assessment of study quality
Validity was assessed on the basis of randomisation, similarity of the treatment groups with respect to prognostic factors, blinding of the outcome assessment, completeness of follow-up, and intention-to-treat analysis. The authors did not state who performed the validity assessment.
Data extraction
Three reviewers independently extracted the data using forms developed for the review. For each group, the ln hazard ratio (HR) and its variance were calculated for overall survival and disease-free survival (the methods used to derive these values were stated). Reported adverse effects were extracted from studies comparing chemotherapy with 
Methods of synthesis
How were the studies combined? Studies that reported surgical staging of the cancer were combined using a random-effects meta-analysis. The pooled HR and 95% confidence intervals (CIs) were calculated for adjuvant chemotherapy compared with radiotherapy and for adjuvant chemotherapy compared with observation (with treatment of progression of the disease). Adverse effects were tabulated by trial, but there was no synthesis.
How were differences between studies investigated?
Subgroup analyses were used to look for differences in effect between trials of chemotherapy versus whole abdominal radiotherapy and chemotherapy versus intraperitoneal P32 radiotherapy. A sensitivity analysis was performed to see the effect of platinum-based chemotherapy in comparisons of chemotherapy versus observation and chemotherapy versus radiotherapy.
Results of the review
Fifteen RCTs (3,162 women) were included. Ten of these RCTs were included in the meta-analysis.
Radiotherapy versus no treatment: the one identified RCT did not report results for each treatment arm.
Chemotherapy versus radiotherapy (5 RCTs, 862 women): in all these RCTs, the treatment groups were similar at baseline with respect to prognostic factors. There was no significant difference in overall survival or disease-free survival between chemotherapy and radiotherapy. The HR was 0.85 (95% CI: 0.62, 1.17) for overall survival and 0.94 (95% CI: 0.56, 1.59) for disease-free survival. Significant heterogeneity was found. A subgroup analysis showed no significant difference between chemotherapy and whole abdomen radiotherapy, between chemotherapy and P32 radiotherapy, or between platinum-based chemotherapy and P32 radiotherapy (the results were reported).
Chemotherapy plus radiotherapy versus radiotherapy alone (2 RCTs, 242 women): the studies compared whole abdominal radiotherapy with pelvic radiotherapy plus chemotherapy. In neither study were the treatment groups similar at baseline with respect to prognostic factors. Neither study presented extractable quantitative data. The individual studies showed no significant difference in survival between the treatments.
Chemotherapy versus no treatment (5 RCTs, 1234 women): 75% of the patients came from 2 RCTs. The RCTs were all of a good quality. The meta-analysis showed that chemotherapy significantly improved overall survival and disease-free survival. The HR was 0.71 (95% CI: 0.63, 0.80) for overall survival and 0.68 (95% CI: 0.59, 0.79) for disease-free survival.
The analysis was repeated after removing the one RCT that did not use a platinum-based chemotherapy regimen.
Neither the results for overall survival nor disease-free survival were altered (the results were reported).
